|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 600 Massachusetts Ave, NW |
Address2 | SUITE 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
TYPE OF REPORT | 8. Year | 2020 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Raymond Gill |
Date | 9/29/2021 10:12:25 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019;
H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245)
S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019;
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020
H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and
H.R.3055, the FY2020 Consolidated measure.
H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues.
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R.6201 - Families First Coronavirus Response Act
S. 3548 - CARES Act (Coronavirus Stimulus 3)
H.R.133 - Consolidated Appropriations Act, 2021
H.R. 4378 - Continuing Appropriations Act and Health Extenders Act
H.R. 133 - Consolidated Appropriations Act, 2021
H.R. 8337 - Continuing Appropriations Act of 2021
- Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
- Strategic National Stockpile (SNS) Funding and Oversight
- Patient access to Part B medicines during the COVID-19 public health emergency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Matthew |
Sulkala |
|
|
|
Catherine |
Phillips |
|
|
|
Elise |
Conner |
|
|
|
Vanessa |
Gannon |
|
|
|
Thomas |
Stoll |
|
|
|
Ravi |
Upadhyay |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 1224, Stop STALLING Act
S. 1416 - Affordable Prescriptions for Patients Act of 2019
H.R. 3991-Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019
H.R. 5133--Affordable Prescriptions for Patients Through Promoting Competition Act of 2019
H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020
H.R. 1503 - the Orange Book Transparency Act; and
H.R. 1520 - Orange Book Transparency Act of 2019;
H.R. 3 - Lower Drug Costs Now Act of 2019
- Intellectual property and process patent issues
- Patent litigation reform
- IPR process
- Section 101 Reform
- Domestic and international compulsory licensing issues
- March-in Rights
- Product hopping
- Orange and purple book disclosures
- Hatch Waxman litigation
- Trade secret protections
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
S. 3548 - CARES Act (Coronavirus Stimulus 3)
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R.6201 - Families First Coronavirus Response Act
H.R.4100 - DISARM Act of 2019
S.340- CREATES Act of 2019
H.R. 2113 - The Prescription Drug STAR Act
H.R. 1520, the Purple Book
H.R. 1499, the Protecting Cok Continuity Act;
H.R.3: Lower Drug Costs Now Act of 2019
S.1895, Lower Health Care Costs Act of 2019
S.551, REFUND Act of 2019
S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020
H.R.133 - Consolidated Appropriations Act, 2021
H.R. 6800 - The Heroes Act (HCR)
S. 4626, SAFE DATA Act
S. 3456, Consumer Data Privacy and Security Act
H.R. 2013, Information Transparency & Personal Data Control Act
S. 2968, Consumer Online Privacy Rights Ac
- Issues related to the 340B Drug Discount Program
- Issues relating to drug pricing
- Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives.
- Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars.
- General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
- Issues related to healthcare legislation
- Patient access to Part B medicines during the COVID-19 public health emergency
- Issues relating to privacy and securing the data of and personal information of consumers
- Issues relating to medical research data
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Vanessa |
Gannon |
|
|
|
Ravi |
Upadhyay |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.3 - Lower Drug Costs Now Act of 2019
S.977 - Transparent Drug Pricing Act of 2019
S.551, REFUND Act of 2019
H.R. 1520, the Purple Book Continuity Act
H.R. 1503, the Orange Book Transparency Act;
H.R. 1499, the Protecting Consumer Access to Generic Drugs Act
H.R. 965, the CREATES Act
H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22).
S.1895, Lower Health Care Costs Act of 2019.
S. 2543, Prescription Drug Pricing Reduction Act of 2019.
H.R.19, Lower Costs, More Cures Act of 2019.
S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act
S. 3129, Lower Cost, More Cures Act of 2019
H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act
H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act
- Issues related to Medicare and Medicaid coverage and reimbursement
- Issues related to the 340B Drug Discount Program
- Issues related to drug pricing
- Medicare reimbursement for biosimilars
- MACRA treatment and reimbursement of Part B drugs
- Medicare payments for inpatient antimicrobials
- Issues related to drug importation
- Issues related to the International Pricing Index for Medicare Part B
- Issues related to CMMI
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Vanessa |
Gannon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R.4549 - American Innovation and Competitiveness Act of 2019
S. 4822 - American Innovation and Jobs Act
- Issues related to R&D tax deductions and expense amortization
- Issues related to supply chain incentives
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
|
Dan |
Neves |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R.2209 - Fixing Global Freeloading Act
- Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
- Issues related to the United States-Mexico-Canada Agreement
- Issues related to other Free Trade Agreements (UK, Kenya, Chile, Colombia, Peru, CAFTA-DR)
- Issues related to compulsory licensing of foriegn patents
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Catherine |
Phillips |
|
|
|
Elise |
Conner |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
S. 3548 - CARES Act (Coronavirus Stimulus 3)
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
H.R.6201 - Families First Coronavirus Response Act
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (No bill number yet)
H.R.133 - Consolidated Appropriations Act, 2021
- Issues related to public health protection including influenza development and preparedness
- Issues related to antimicrobial and antiviral research and product development
- Issues related to novel coronavirus and COVID-19 research and product development
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrew |
Womack |
|
|
|
Vanessa |
Gannon |
|
|
|
Elise |
Conner |
|
|
|
David |
Burt |
|
|
|
Catherine |
Phillips |
|
|
|
Dan |
Neves |
|
|
|
Valerie |
Reynolds |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
S.2543: Prescription Drug Pricing Reduction Act of 2019.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.19: Lower Costs, More Cures Act of 2019.
S.551, REFUND Act of 2019
HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
- Drug pricing issues
- Prescription Drug User Fee Act reauthorization
- Issues related to prescription drug value
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Andrew |
Womack |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Vanessa |
Gannon |
|
|
|
Ravi |
Upadhyay |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIN
16. Specific lobbying issues
Foreign Investment Risk Review Modernization Act (FIRRMA) H.R. 5841/S. 2098 legislation that would reform the Committee on Foreign Investment in the United States (CFIUS)
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catherine |
Phillips |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
S.4049 - National Defense Authorization Act for Fiscal Year 2021
H.R.2500 - National Defense Authorization Act for Fiscal Year 2021
H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021
- Issues related to pharmaceutical supply chains and related security issues
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Matthew |
Sulkala |
|
|
|
Andrew |
Womack |
|
|
|
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
|
Ravi |
Upadhyay |
|
|
|
Dan |
Neves |
|
|
|
Valerie |
Reynolds |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
H.R. 6443, Securing the National Supply Chain Act
H.R. 6630, Securing Americas Critical Minerals Supply Chain Act
H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act
H.R. 6713, Furthering Our Recovery With American Research and Development
H.R. 6863, COVID-19 Accountability Act
H.R. 6903, Bring American Companies Home Act
H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes.
H.R. 7505, American Innovation Act
H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions.
H.R. 7537, Infectious Disease Therapies Research and Innovation Act
H.R. 7555, More Cures Act
H.R. 7556, Start-ups for Cures Act
S. 3593, Furthering Our Recovery With American Research and Development
S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act
S. 3827, Medical Supplies for Pandemics Act
H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act
H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act
S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act
S. 3478, Commission on Americas Medical Security Act
S. 3538, Strengthening America's Supply Chain and National Security Act
S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537)
H.R. 6531, Medical Supplies for Pandemics Act
H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes.
H.R. 6049, Medical Supply Chain Security Act
H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes
H.R. 6080, Preventing Drug Shortages Act
H.R. 6393, Strengthening America's Supply Chain and National Security Act
H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act
H.R. 6670, Prescription for American Drug Independence Act
H.R. 6708, Securing Americas Medicine Cabinet Act
H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act
S. 2723, Mitigating Emergency Drug Shortages Act
S. 3343, Medical Supply Chain Security Act
S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act
S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act
S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act
H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021
- Issues related to pharmaceutical supply chains
- Issues related to reporting on location of origin of pharmaceutical products
- Issues related to drug shortages
- Issues related to pharmaceutical manufacturing
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Andrew |
Womack |
|
|
|
Matthew |
Sulkala |
|
|
|
Ravi |
Upadhyay |
|
|
|
Thomas |
Stoll |
|
|
|
Dan |
Neves |
|
|
|
Valerie |
Reynolds |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
S. 386 - Fairness for High-Skilled Immigrants Act of 2019
S. 328 - Startup Act
S. 2603 - RELIEF Act
H.R. 1044 - Fairness for High-Skilled Immigrants Act of 2020
H.R. 5327 - Resolving Extended Limbo for Immigrant Employees and Families Act
- Issues relating to limits and restrictions on the immigration of high skilled workers
- Issues relating to the immigration of medical researchers
17. House(s) of Congress and Federal agencies Check if None
Homeland Security - Dept of (DHS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |